IBC
13.5.2019 14:26:08 CEST | Business Wire | Press release
TM Forum, the industry association driving digital transformation through collaboration, and IBC, the world’s most influential media, entertainment and technology show, unveiled the details of three joint proof-of-concept Catalyst projects to be demonstrated at Digital Transformation World in Nice, France, May 14-16, 2019.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190513005442/en/
Catalysts are proof-of-concept projects developed collaboratively. These projects bring together companies large and small to create innovate solutions to common challenges demonstrating how this can be achieved leveraging key TM Forum best practices and standards.
These three unique Media-Telecom Convergence Catalyst projects are the first results of IBC and TM Forum’s collaboration aimed at driving open innovation between the telecoms and media industries. Featured among the 32 projects demonstrated at Digital Transformation World, they incorporate some of today’s most complex business and technology challenges today, including 5G, data management, virtual and augmented reality, edge computing, AI and the automation of business processes for regulatory compliance.
The three Media-Telecom Catalysts are:
-
5G-Enabled
Tourism Experience
This Catalyst explores ways of creating a pop-up network for delivery of high throughput broadcasting to distant points of fiber presence via mmWave connection. The project investigates how to deliver rich and engaging video-based experiences to users exploring an area of the Roman Baths in the UK and allows a mobile device to view a place as it would have been in the past. Champions: Aardman Entertainment, BBC R&D Participants: Bristol University, Cambridge Communications Systems Ltd., Zeetta Networks Ltd.
-
AI
Indexing for Regulatory Practice
This Catalyst is exploring ways to intelligently automate the identification of on-air content using AI in order to measure and report against compliance metrics set by external regulatory bodies, as well as for accurate measurement of internal editorial, creative and technical standards. Champions: Associated Press, Al Jazeera, RTE; Participants: Metaliquid, QCRI, Tech Mahindra, V-Nova
-
Mobile
News Gathering Using AI-Powered Compression
This Catalyst is working to empower newsrooms and journalists through improved intelligence for the mobile reporter in the field and faster time-to-air for both live and pre-recorded content. It leverages AI and techniques for improved bandwidth utilization through advanced compression techniques. Champions: Associated Press, Al Jazeera, RTE; Participant: V-Nova
“The convergence between telecom and media and entertainment has opened up exciting opportunities for our members to work alongside some of the world’s leading media companies to solve pressing business challenges,” said Andy Tiller, Executive Vice President, Collaboration and Innovation, TM Forum. “These three projects truly showcase how the power of collaboration helped find unique real-world solutions to problems faced by both industries – not only transforming businesses but consumer experience as well."
“As the pace of technology disruption and convergence accelerates, the rapid-fire Media-Telco Catalyst model for cross-sector innovation, partnerships and broader digital transformation is already proving a game-changing approach.” said Imran Sroya, Director, IBC. “We are delighted with the progress of the first three Catalyst projects and look forward to showcasing them at Digital Transformation World this month and at IBC in Amsterdam in September.”
Learn more about TM Forum’s Catalyst program at Digital Transformation World in Nice, France, May 14-16, 2019. With a focus on intelligent operations for a 5G world, Digital Transformation World showcases how businesses can seize opportunity and remain competitive in a rapidly evolving digital world. Click here for the latest event agenda: https://dtw.tmforum.org/agenda/
–Ends –
About TM Forum
TM Forum is an association of over 850-member companies’ customers across 180 countries. We drive collaboration and collective problem-solving to maximize the business success of communication and digital service providers and their ecosystem of suppliers around the world. Today, our focus is on supporting members as they navigate their unique digital transformation journeys, providing practical and proven assets and tools to accelerate execution and platforms to facilitate collaborative problem solving and innovation. Learn more at www.tmforum.org.
About IBC
IBC is the world’s most influential media, entertainment and technology show, attracting 55,000+ attendees from more than 170 countries and combining a highly respected and peer-reviewed conference with an exhibition that showcases 1,700+ leading industry suppliers of state-of-the-art technology. In addition to the world-class exhibition and conference, IBC also encompasses the IBC Daily, IBCTV and IBC365.
IBC365 provides year-round insight and opinion into the hot topics and key trends from leading industry journalists, along with insightful whitepapers, peer reviewed technical papers, highly engaging webinars and an expansive video library.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190513005442/en/
Contact:
CCgroup PR Anais Merlin E: TMForum@ccgrouppr.com T: +44 203 824 9200
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
